Abstract The 2-amino-3-benzoylthiophene derivative PD 81,723 is an allosteric enhancer of agonist binding to brain A, adenosine receptors. One aim of this study was to characterize and contrast the effects of PD 81,723 on the A, receptormediated negative dromotropic and Al, receptor-mediated vasodilatory actions of adenosine and of a nonmetabolizable and unselective N6-(3-pentyl)adenosine derivative. A second aim was to determine the mechanism of action of PD 81,723. In guinea pig isolated hearts, PD 81,723 potentiated the adenosine and the N6-(3-pentyl)adenosine derivative-induced prolongations of the stimulus-to-His bundle (S-H) interval in a concentration-dependent manner. PD 81,723 (30 ,umol Key Words * isolated heart * radioligand binding * guinea pigs inhibitor dipyridamole have been shown to terminate supraventricular and catecholamine-sensitive tachycardias in humans.5-8 Thus, modulation of adenosine metabolism and/or adenosine receptor activation may prove beneficial in the treatment of cardiac arrhythmias and ischemic heart disease. A number of pharmacologic approaches can be used to modulate the adenosine system (ie, adenosine's metabolic pathways and receptors). Direct-acting agonists, such as adenosine or synthetic adenosine analogues, mimic the effects of the endogenous nucleoside.69 However, adenosine receptors are present in many organ systems; thus, their indiscriminate activation by directacting agonists results in numerous systemic effects.10 Inhibitors of the metabolism of adenosine (ie, adenosine deaminase and adenosine kinase inhibitors and nucleoside uptake blockers), by increasing interstitial and plasma levels of the nucleoside, enhance the cardiovascular actions of exogenous and endogenous adenosine."1-3Allosteric enhancers of the actions of adenosine have recently emerged as alternative agents to direct-acting adenosine agonists and to inhibitors of the metabolism of adenosine.14 The 2-amino-3-benzoylthiophene derivative PD 81,723 has been shown to enhance the binding of adenosine agonists to A, receptors in brain membranes and therefore has been classified as an allosteric enhancer.14 PD 81,723 has also been shown to specifically potentiate A, receptor-mediated reby guest on October 22, 2017
300%, respectively. PD 81,723 also increased the fraction of A, receptors in the high-affinity binding state by an average of 56±13%. The dissociation rate of [3H]CHA from guinea pig A denosine is an autacoid (or local hormone) that modulates numerous functions of the cardiovascular system."12 In the heart, in addition to being a potent vasodilator, adenosine slows heart rate (negative chronotropic effect), slows atrioventricular (AV) nodal conduction (negative dromotropic effect), and antagonizes the stimulatory effects (ie, inotropic and arrhythmogenic) of catecholamines.' These effects of adenosine, which increase the supply of oxygen and decrease cardiac work, are cardioprotective. Consistent with this cardioprotective action, adenosine, adenosine receptor agonists, and agents that increase the interstitial concentration of adenosine (eg, nucleoside uptake blockers and adenosine deaminase and adenosine kinase inhibitors) have been shown to reduce myocardial cell damage and dysfunction during hypoxia and ischemia (for extended reference lists, refer to References 1, 3, and 4). Adenosine and the nucleoside uptake guinea pigs inhibitor dipyridamole have been shown to terminate supraventricular and catecholamine-sensitive tachycardias in humans.5-8 Thus, modulation of adenosine metabolism and/or adenosine receptor activation may prove beneficial in the treatment of cardiac arrhythmias and ischemic heart disease. A number of pharmacologic approaches can be used to modulate the adenosine system (ie, adenosine's metabolic pathways and receptors). Direct-acting agonists, such as adenosine or synthetic adenosine analogues, mimic the effects of the endogenous nucleoside.69 However, adenosine receptors are present in many organ systems; thus, their indiscriminate activation by directacting agonists results in numerous systemic effects. 10 Inhibitors of the metabolism of adenosine (ie, adenosine deaminase and adenosine kinase inhibitors and nucleoside uptake blockers), by increasing interstitial and plasma levels of the nucleoside, enhance the cardiovascular actions of exogenous and endogenous adenosine."1-3Allosteric enhancers of the actions of adenosine have recently emerged as alternative agents to direct-acting adenosine agonists and to inhibitors of the metabolism of adenosine.14 The 2-amino-3-benzoylthiophene derivative PD 81,723 has been shown to enhance sponses in guinea pig and rat hearts.15 '16 In contrast to direct-acting adenosine agonists, allosteric enhancers could provide site-and event-specific potentiation of the effects of adenosine.
The aims of the present study were twofold. The first objective was to characterize the potentiation of the negative dromotropic action of adenosine by the allosteric enhancer PD 81,723 in guinea pig hearts and to compare the potentiation by PD 81,723 with that caused by the nucleoside uptake inhibitor draflazine. 17 The second objective was to characterize the effects of PD 81,723 on radioligand binding to . The final concentration of DMSO in the perfusion fluid and the incubation buffer in radioligand binding assays was <0.5% (volvol) , which had no effect on the stimulus-to-His bundle (S-H) interval prolongation or radioligand binding parameters.
Experimental Preparations Isolated Hearts
Guinea pigs (Hartley) of either sex weighing between 250 and 300 g were anesthetized with methoxyflurane and killed by cervical dislocation. The hearts were quickly excised, rinsed in ice-cold Krebs-Henseleit solution, and perfused through the aorta at a constant flow of 10 mL/min. The perfusate was an oxygenated Krebs-Henseleit solution of the following composition (mmol/L): NaCl 117.9, KCl 4.5, CaCl2 2.5, MgSO4 1.18, KH2P04 1.18, pyruvate 2.0, glucose 5.5, Na2EDTA 0.57, ascorbic acid 0.007, and NaHCO3 25.0. The solution was gassed with 95% 02/5% CO2 (pH 7.4), and the temperature was maintained at 35.0+0.5°C. The sinoatrial nodal region and part of the right atrium were excised to facilitate electrical pacing of the heart and to expose the region of the AV node. The hearts were paced via bipolar electrodes positioned on the left atrium or interatrial septum. An interval generator (model 1830, World Precision Instruments) and a stimulus isolation unit (model 1880, World Precision Instruments) were used to deliver square-wave stimulus pulses of 3-millisecond duration and of an amplitude at least twice the threshold intensity. His bundle electrograms were recorded with unipolar extracellular electrodes placed in the region of the AV node. The His bundle electrogram was filtered and amplified with a differential amplifier (Tektronix) and displayed on a dual-beam storage oscilloscope (Tektronix). Because the depressant effect of adenosine on AV nodal conduction (negative dromotropic effect) is confined to the proximal part of the AV node, the S-H interval was used as a measurement of the negative dromotropic effect of adenosine.9 The S-H interval was measured directly from the oscilloscope display at a sweep speed of 10 ms/cm. After dissection and instrumentation, the hearts were allowed to equilibrate for 30 minutes before data were collected. Experimental interventions were preceded and followed by measurements of the baseline S-H interval, and if preintervention and postintervention values differed by >15%, the data were discarded. Unless otherwise noted, whenever interventions caused AV block, the maximal stable S-H interval before the onset of AV block was used for data analysis. The effects of all interventions were determined during steady state; generally, this required a 5-minute infusion of adenosine and a 15-minute infusion of all other drugs.
During protocols evaluating coronary flow responses (A2a adenosine receptor-mediated effect), the coronary perfusion pressure (in millimeters of mercury) was monitored throughout the experiment. Because hearts were perfused at constant flow, the coronary conductance (in millimeters per minute per millimeters of mercury) was calculated as the ratio between the coronary perfusion rate (10 mL/min) and the perfusion pressure (in millimeters of mercury).
Adenosine Assay
The concentrations of adenosine in the samples of cardiac effluent collected from the pulmonary artery were determined by reversed-phase high-performance liquid chromatography according to a previously published isocratic method.19 Cardiac effluent samples were collected for 15 seconds at predetermined time points and frozen at -80°C yntil analyzed.
Samples were thawed, and 200-,L aliquots were assayed for adenosine content. Adenosine in the samples was identified by retention time and verified by enzymatic degradation to inosine using adenosine deaminase. The concentrations of adenosine in the samples were determined by comparison of peak areas from experimental samples with those of standard samples containing known quantities of adenosine.
Membrane Preparation
Human atrial and guinea pig atrial, ventricular, and brain tissues were separately minced and then homogenized in ice-cold 50 mmol/L Tris-HCl, pH 7.4. Homogenates were filtered through cotton gauze and centrifuged at 48 OOOg for 15 minutes. The membrane pellets were washed twice by resuspension in fresh buffer and centrifugation. Final pellets were resuspended in 50 mmol/L Tris-HCl, pH 7.4, and frozen at -800C. Isolated Heart Protocols Effects ofAllosteric Enhancer PD 81,723 and Nucleoside Uptake Inhibitor Draflazine on Negative Dromotropic Action ofAdenosine
In each of the 10 hearts in this series of experiments, concentration-response curves for adenosine (1 to 10 ,umol/ L)-induced prolongation of the S-H interval (negative dromotropic effect) were determined in the absence and presence of PD 81,723. In each heart, a control adenosine concentrationresponse relation (ie, in the absence of PD 81,723) was initially determined. After recording the baseline S-H interval, adenosine was infused at rates to achieve increasingly higher perfusate concentrations until second-degree AV block occurred. After a 15-minute washout of adenosine, PD 81,723 was infused at increasing rates to achieve perfusate concentrations of 2.5, 5, 10, and 30 .mol/L in that order. The adenosine concentration-response relation was determined in the presence of each concentration of PD 81,723. The corresponding S-H intervals were recorded continuously throughout the experiment. In each heart, the effects of a maximum of three concentrations of PD 81,723 on the adenosine concentration-response relation were determined. In a separate group of hearts (n=4), the concentration-response relation for adenosine-induced prolongation of the S-H interval was determined in the absence and presence of draflazine (0.1 gmol/L). Concentration-response relations for A1 and A2,, receptormediated responses to the nonmetabolizable and nonselective adenosine analogue PCPN were determined in the absence and presence of PD 81,723. In the first series of experiments, carried out in constant-flow (10 mL/min) perfused hearts (n=5), the concentration-response relations for PCPN-induced prolongation of the S-H interval (A, receptor-mediated effect) and reduction of coronary perfusion pressure (A2. receptor-mediated effect) were determined. In each heart, after the baseline S-H interval was recorded, PCPN was infused at rates to achieve increasingly higher perfusate concentrations until second-degree AV block occurred. The steady-state S-H interval prolongation and maximum decrease in coronary perfusion pressure were recorded at each concentration of PCPN. The coronary conductance was calculated as the ratio between the coronary perfusion rate (10 mL/min) and the perfusion pressure. In a second group of constant-flow perfused hearts (n=5), the steady-state prolongation of the S-H interval and the increase in coronary conductance induced by PCPN were determined in the absence and presence of PD 81,723 (2.5 ,umol/L).
Determination of Rank Order of Potency for Negative Dromotropic Effect ofA1 Adenosine Receptor Agonists
The potencies (ECso values) of the adenosine agonists CCPA, CHA, 2-CADO, and R-and S-PIA necessary to prolong the S-H interval were determined in 12 isolated perfused hearts. In each heart after the baseline S-H interval was recorded, an agonist was infused at rates to achieve increasingly higher perfusate concentrations until seconddegree AV block occurred. After a 10-minute washout of the agonist, the concentration-response relation for another agonist was determined. A maximum of three agonist concentration-response relations was determined in any one heart. The S-H intervals were recorded continuously throughout the experiment.
Radioligand Binding Protocols
To complement the functional studies described above, the effects of PD 81,723 on the binding of adenosine receptor ligands to cardiac and brain membranes were determined. ,umol/L, respectively (Fig 1) . Similarly, draflazine significantly potentiated the negative dromotropic effect of adenosine (Fig 2) . The EC50 value for the S-H interval prolongation induced by adenosine was 6.0±+ 0.21 ,umol/L in the absence and 0.18±0.05 ,umol/L in the presence of 0.1 pmol/L draflazine (Fig 2) . Although both PD 81,723 and draflazine potentiated the negative dromotropic effect of adenosine, only draflazine caused a concomitant increase (47%) in the concentration of adenosine in the cardiac effluent (Fig  3) . PD (Fig 3B) . In the presence of PD 81,723 (5 ,umol/L), the same perfusate concentration of adenosine (ie, 3 gmol/L) caused a similar (P>.05) increase in the concentration of this nucleoside in the cardiac effluent to 1.24±0.09 ,mol/L (Fig 3B) . In contrast, in the presence of draflazine (0.02 ,umol/L) the same perfusate concentration of adenosine (3 gumol/L) resulted in a significant increase in the concentration of this nucleoside in the cardiac effluent to 2.5±0.14 ,umol/L, a value that is over 1.5 -fold higher than that obtained during the infusion of adenosine alone (Fig 3B) . (Fig 4) . PCPN alone in a concentration-dependent manner prolonged the S-H interval (A1 response) and increased the coronary conductance (A2a response), with EC50 values of 8.3 ±1.1 and 8.0±0.9 nmol/L, respectively (Fig 5) . Thus, PCPN was equipotent for A1 and A2, receptor-mediated responses. As shown in Fig 4A, (Fig 7) . The (Fig 8) [3HICHA, (nM) (Fig 10) . In the high-affinity binding state increased an average of 56+13%, whereas the fraction of receptors in the low-affinity state decreased accordingly (n=3, Fig 10) (Fig 11) . (Fig 12B) . Lack (Figs 3 and 13 ). In contrast to PD 81,723, the potentiation of the negative inhibitors, such as dipyridamole12 and draflazine (Fig 3) A, receptor-mediated negative dromotropic effect of adenosine by a mechanism that is independent of er, with K, values of nucleoside uptake inhibition. pectively (Fig 13) .
The results of the present study also demonstrate for in the first time that the enhancement of the negative (Fig 1) (Fig 9) . This finding suggests that high-affinity binding detected by the agonist represents only a fraction of the total receptor population. Thus, there are at least two mechanisms whereby PD 81,723 may increase the Bm. value of an agonist: (1) PD 81,723 may improve the coupling of the A, receptor to the G protein and thereby increase the fraction of receptors in the highaffinity binding state. (2) In addition or alternatively, PD 81,723 may act directly on the A1 receptor to increase the affinity with which agonists bind to the low-affinity state of the receptor. In support of the former hypothesis, PD 81,723 increased the fraction of receptors in the high-affinity binding state by an average of 56±13% (Fig 10) . To determine the effect of PD 81,723 on G protein-receptor interactions, the inhibition of agonist binding by the nonhydrolyzable GTP analogue Gpp(NH)p was used as a functional assay for the efficacy of receptor to G protein coupling.29 PD 81,723 reduced the potency of Gpp(NH)p to inhibit the specific binding of [3H] CHA by approximately sixfold and ninefold in cardiac and forebrain membranes, respectively (Fig 11) . This finding can be interpreted to indicate that PD 81,723 improves the coupling of A, adenosine receptors to G proteins. However, additional studies will be required to conclusively establish the involvement of receptor-G protein interactions in the mechanism of action of PD 81,723.
Implications
The nucleoside adenosine has been shown to be cardioprotective during periods of ischemia and hypoxia.4 A similar protective role for adenosine and adenosine analogues has also been shown in brain, liver, and intestine.'0 32 This and other potentially beneficial actions of adenosine have led to increased interest in the development of adenosine-related drugs targeted to ameliorate conditions such as myocardial ischemia and stroke.430 Because direct-acting receptor agonists will activate A1 adenosine receptors in multiple organ systems, new approaches are needed to achieve event and site specificity. Allosteric enhancers of adenosine may prove to be valuable alternatives to direct-acting adenosine agonists. Such agents should selectively augment the response to adenosine in only those organs or localized areas of a given organ in which production of adenosine is increased. For instance, the cardiac effects of allosteric enhancers will be most prominent in areas of the myocardium where oxygenation is inadequate. These agents will act as site-specific (02-deprived areas only) and event-specific (ischemia) potentiators of the effects of adenosine. In the absence of increased production of this nucleoside (eg, normoxia), allosteric enhancers of adenosine should have little or no effect. In addition, allosteric enhancers may potentiate only those responses mediated by a given receptor subtype, such as the A1 receptor in the case of PD 81,723. Thus, PD 81,723 and similar compounds may prove to be ideal therapeutic approaches to selectively and specifically amplify the actions of endogenous adenosine. In the accompanying study in this issue of Circulation Research,33 we show that PD 81,723 augments A, but not A2a receptor-mediated actions of endogenous adenosine in isolated and in situ guinea pig hearts.
